Oesophago-gastric cancer: assessment and management in adults

In June 2025, we reviewed the recommendation on localised oesophageal and oesophago-gastric junctional adenocarcinoma.

Surveillance decision

We will not update the recommendation. Currently the recommendation is to offer a choice of chemotherapy (before or before and after surgery) or chemoradiotherapy (before surgery). Given the evidence available from a high quality systematic review and recently available randomised controlled trials, we could not recommend one intervention in preference to the other, and therefore, there does not appear to be an impact on current NICE guidance.